Table 1 Baseline characteristics of patients stratified by the TyG index tertiles
Variable | T1 (n = 210) | T2 (n = 211) | T3 (n = 212) | P value |
|---|---|---|---|---|
Age, years | 70.28 ± 10.53 | 67.50 ± 10.46 | 66.31 ± 10.91 | < 0.001 |
Female, n (%) | 67 (31.9) | 71 (33.6) | 70 (33.0) | 0.928 |
BMI, kg/m2 | 24.24 ± 2.93 | 24.99 ± 2.85 | 25.45 ± 3.40 | < 0.001 |
Smoking, n (%) | 90 (42.9) | 95 (45.0) | 99 (46.7) | 0.729 |
Previous PCI, n (%) | 28 (13.3) | 16 (7.6) | 24 (11.3) | 0.154 |
COPD, n (%) | 11 (5.2) | 8 (3.8) | 9 (4.2) | 0.762 |
Hypertension, n (%) | 156 (74.3) | 165 (78.2) | 156 (73.6) | 0.495 |
AF, n (%) | 19 (9.0) | 13 (6.2) | 20 (9.4) | 0.408 |
Previous stroke, n (%) | 15 (7.1) | 8 (3.8) | 13 (6.1) | 0.313 |
SBP, mmHg | 133.19 ± 21.80 | 134.00 ± 22.87 | 134.79 ± 21.21 | 0.459 |
HR, bpm | 77.51 ± 13.86 | 77.36 ± 14.72 | 81.45 ± 15.72 | 0.006 |
cTnT, pg/mL | 25.90 (13.80, 550.40) | 28.66 (13.00, 502.10) | 49.17 (14.00, 459.30) | 0.388 |
BNP, pg/mL | 97.90 (40.55, 304.25) | 99.60 (34.70, 328.80) | 137.18 (45.93, 485.15) | 0.132 |
Scr, µmol/L | 79.85 (66.70, 98.35) | 76.00 (64.00, 92.70) | 78.55 (63.03, 101.20) | 0.248 |
Uric acid, µmol/L | 369.76 ± 117.54 | 386.24 ± 125.92 | 379.99 ± 127.59 | 0.387 |
FBG, mmol/L | 6.70 ± 2.06 | 8.38 ± 2.49 | 10.28 ± 3.85 | < 0.001 |
HbA1c | 7.00 ± 1.40 | 7.74 ± 1.78 | 8.04 ± 1.78 | < 0.001 |
TG, mmol/L | 1.01 ± 0.29 | 1.38 ± 0.39 | 2.22 ± 0.99 | < 0.001 |
TC, mmol/L | 3.98 ± 1.13 | 4.40 ± 1.28 | 4.78 ± 1.27 | < 0.001 |
HDL-C, mmol/L | 1.17 ± 0.30 | 1.09 ± 0.28 | 1.12 ± 0.30 | 0.012 |
LDL-C, mmol/L | 2.37 ± 0.78 | 2.68 ± 0.89 | 2.93 ± 0.90 | < 0.001 |
LVEF | 55.01 ± 9.39 | 55.43 ± 9.37 | 53.28 ± 10.23 | 0.053 |
AMI, n (%) | 89 (42.4) | 89 (42.2) | 106 (50.0) | 0.183 |
Diagnosis, n (%) | 0.429 | |||
 CCS | 33 (15.7) | 35 (16.6) | 22 (10.4) |  |
 UA | 88 (41.9) | 87 (41.2) | 84 (39.6) |  |
 NSTEMI | 48 (22.9) | 43 (20.4) | 53 (25.0) |  |
 STEMI | 41 (19.5) | 46 (21.8) | 53 (25.0) |  |
Aspirin, n (%) | 204 (97.1) | 206 (97.6) | 203 (95.3) | 0.519 |
P2Y12 receptor inhibitor, n (%) | 208 (99.0) | 210 (99.5) | 208 (98.1) | 0.368 |
Statins, n (%) | 203 (96.7) | 206 (97.6) | 209 (98.6) | 0.432 |
β-Blockers, n (%) | 145 (69.0) | 145 (68.7) | 162 (76.4) | 0.141 |
ACEI/ARB, n (%) | 100 (47.6) | 108 (51.2) | 112 (52.8) | 0.550 |
Diuretics, n (%) | 39 (18.6) | 47 (22.3) | 53 (25.0) | 0.278 |
Insulin, n (%) | 45 (21.4) | 62 (29.4) | 60 (28.3) | 0.133 |
Oral hypoglycemic agents, n (%) | 145 (69.0) | 156 (73.9) | 149 (70.3) | 0.516 |
MVD, n (%) | 151 (71.9) | 154 (73.0) | 168 (79.2) | 0.172 |
LM, n (%) | 11 (5.2) | 24 (11.4) | 10 (4.7) | 0.013 |
Calcified lesions, n (%) | 38 (18.1) | 39 (18.5) | 42 (19.8) | 0.894 |
Thrombosis, n (%) | 19 (9.0) | 16 (7.6) | 23 (10.8) | 0.507 |
Long lesion, n (%) | 125 (59.9) | 130 (61.6) | 141 (66.5) | 0.314 |
CTO, n (%) | 41 (19.5) | 39 (18.5) | 59 (27.8) | 0.039 |
Number of stents | 1.51 ± 0.92 | 1.51 ± 0.94 | 1.58 ± 0.96 | 0.643 |
Length of stents, mm | 39.18 ± 26.43 | 40.05 ± 28.58 | 43.20 ± 29.07 | 0.301 |
TyG index | 8.50 ± 0.32 | 9.05 ± 0.13 | 9.67 ± 0.38 | < 0.001 |
bSS | 14.00 (8.00, 21.00) | 16.00 (9.00, 21.50) | 15.75 (10.00, 21.38) | 0.379 |
rSS | 3.00 (0.00, 8.00) | 5.00 (0.00, 9.00) | 4.00 (1.00, 9.00) | 0.286 |